RU2193881C2 - Фармацевтический препарат для орального применения, содержащий ибандронат - Google Patents
Фармацевтический препарат для орального применения, содержащий ибандронат Download PDFInfo
- Publication number
- RU2193881C2 RU2193881C2 RU98120909/14A RU98120909A RU2193881C2 RU 2193881 C2 RU2193881 C2 RU 2193881C2 RU 98120909/14 A RU98120909/14 A RU 98120909/14A RU 98120909 A RU98120909 A RU 98120909A RU 2193881 C2 RU2193881 C2 RU 2193881C2
- Authority
- RU
- Russia
- Prior art keywords
- cellulose
- derivatives
- drug according
- paragraphs
- active substance
- Prior art date
Links
- MPBVHIBUJCELCL-UHFFFAOYSA-N Ibandronate Chemical compound CCCCCN(C)CCC(O)(P(O)(O)=O)P(O)(O)=O MPBVHIBUJCELCL-UHFFFAOYSA-N 0.000 title claims abstract description 13
- 229940015872 ibandronate Drugs 0.000 title claims abstract description 11
- 238000002360 preparation method Methods 0.000 title description 3
- 239000013543 active substance Substances 0.000 claims abstract description 36
- 239000003814 drug Substances 0.000 claims abstract description 12
- 210000004051 gastric juice Anatomy 0.000 claims abstract description 10
- 239000000126 substance Substances 0.000 claims abstract description 7
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 4
- 208000010191 Osteitis Deformans Diseases 0.000 claims abstract description 4
- 208000037147 Hypercalcaemia Diseases 0.000 claims abstract description 3
- 208000003076 Osteolysis Diseases 0.000 claims abstract description 3
- 208000001132 Osteoporosis Diseases 0.000 claims abstract description 3
- 208000027868 Paget disease Diseases 0.000 claims abstract description 3
- 230000000148 hypercalcaemia Effects 0.000 claims abstract description 3
- 208000030915 hypercalcemia disease Diseases 0.000 claims abstract description 3
- 208000029791 lytic metastatic bone lesion Diseases 0.000 claims abstract description 3
- 208000027202 mammary Paget disease Diseases 0.000 claims abstract description 3
- 239000012736 aqueous medium Substances 0.000 claims abstract 2
- 238000000576 coating method Methods 0.000 claims description 23
- 239000011248 coating agent Substances 0.000 claims description 19
- 239000003826 tablet Substances 0.000 claims description 18
- 229940079593 drug Drugs 0.000 claims description 11
- 239000003795 chemical substances by application Substances 0.000 claims description 10
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 10
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 claims description 9
- 229920002678 cellulose Polymers 0.000 claims description 9
- 239000001913 cellulose Substances 0.000 claims description 9
- 235000010980 cellulose Nutrition 0.000 claims description 9
- -1 methyl hydroxypropyl Chemical group 0.000 claims description 9
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 7
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 7
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 7
- 229920003134 Eudragit® polymer Polymers 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 6
- 229920000642 polymer Polymers 0.000 claims description 6
- 229920002472 Starch Polymers 0.000 claims description 5
- 229920001577 copolymer Polymers 0.000 claims description 5
- 235000019698 starch Nutrition 0.000 claims description 5
- 239000008298 dragée Substances 0.000 claims description 4
- 239000000945 filler Substances 0.000 claims description 4
- 239000007888 film coating Substances 0.000 claims description 4
- 238000009501 film coating Methods 0.000 claims description 4
- 239000008187 granular material Substances 0.000 claims description 4
- 239000000843 powder Substances 0.000 claims description 4
- 239000004604 Blowing Agent Substances 0.000 claims description 3
- 150000001720 carbohydrates Chemical class 0.000 claims description 3
- 235000014633 carbohydrates Nutrition 0.000 claims description 3
- 239000003925 fat Substances 0.000 claims description 3
- 229920003145 methacrylic acid copolymer Polymers 0.000 claims description 3
- 230000007935 neutral effect Effects 0.000 claims description 3
- 239000000049 pigment Substances 0.000 claims description 3
- 229920000193 polymethacrylate Polymers 0.000 claims description 3
- 229920002689 polyvinyl acetate Polymers 0.000 claims description 3
- 239000011118 polyvinyl acetate Substances 0.000 claims description 3
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 claims description 2
- JKNCOURZONDCGV-UHFFFAOYSA-N 2-(dimethylamino)ethyl 2-methylprop-2-enoate Chemical compound CN(C)CCOC(=O)C(C)=C JKNCOURZONDCGV-UHFFFAOYSA-N 0.000 claims description 2
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 claims description 2
- GJCOSYZMQJWQCA-UHFFFAOYSA-N 9H-xanthene Chemical compound C1=CC=C2CC3=CC=CC=C3OC2=C1 GJCOSYZMQJWQCA-UHFFFAOYSA-N 0.000 claims description 2
- 244000215068 Acacia senegal Species 0.000 claims description 2
- 229920000623 Cellulose acetate phthalate Polymers 0.000 claims description 2
- 229920001661 Chitosan Polymers 0.000 claims description 2
- 229920001353 Dextrin Polymers 0.000 claims description 2
- 239000004375 Dextrin Substances 0.000 claims description 2
- JIGUQPWFLRLWPJ-UHFFFAOYSA-N Ethyl acrylate Chemical compound CCOC(=O)C=C JIGUQPWFLRLWPJ-UHFFFAOYSA-N 0.000 claims description 2
- 239000001856 Ethyl cellulose Substances 0.000 claims description 2
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims description 2
- 229920000084 Gum arabic Polymers 0.000 claims description 2
- 244000043261 Hevea brasiliensis Species 0.000 claims description 2
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 claims description 2
- 239000004354 Hydroxyethyl cellulose Substances 0.000 claims description 2
- 229920001479 Hydroxyethyl methyl cellulose Polymers 0.000 claims description 2
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 claims description 2
- 229920000881 Modified starch Polymers 0.000 claims description 2
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 2
- 229920001800 Shellac Polymers 0.000 claims description 2
- 229920002125 Sokalan® Polymers 0.000 claims description 2
- 235000010489 acacia gum Nutrition 0.000 claims description 2
- 239000000205 acacia gum Substances 0.000 claims description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 2
- 229940072056 alginate Drugs 0.000 claims description 2
- 235000010443 alginic acid Nutrition 0.000 claims description 2
- 229920000615 alginic acid Polymers 0.000 claims description 2
- 125000000129 anionic group Chemical group 0.000 claims description 2
- 239000011805 ball Substances 0.000 claims description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 2
- 229920003118 cationic copolymer Polymers 0.000 claims description 2
- 229920002301 cellulose acetate Polymers 0.000 claims description 2
- 229940081734 cellulose acetate phthalate Drugs 0.000 claims description 2
- 235000019425 dextrin Nutrition 0.000 claims description 2
- 150000002148 esters Chemical class 0.000 claims description 2
- 229920001249 ethyl cellulose Polymers 0.000 claims description 2
- 235000019325 ethyl cellulose Nutrition 0.000 claims description 2
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 claims description 2
- 229920003063 hydroxymethyl cellulose Polymers 0.000 claims description 2
- 229940031574 hydroxymethyl cellulose Drugs 0.000 claims description 2
- 229920000609 methyl cellulose Polymers 0.000 claims description 2
- 239000001923 methylcellulose Substances 0.000 claims description 2
- 235000010981 methylcellulose Nutrition 0.000 claims description 2
- 235000019426 modified starch Nutrition 0.000 claims description 2
- 229920003052 natural elastomer Polymers 0.000 claims description 2
- 229920001194 natural rubber Polymers 0.000 claims description 2
- PNJWIWWMYCMZRO-UHFFFAOYSA-N pent‐4‐en‐2‐one Natural products CC(=O)CC=C PNJWIWWMYCMZRO-UHFFFAOYSA-N 0.000 claims description 2
- 239000004014 plasticizer Substances 0.000 claims description 2
- 239000004584 polyacrylic acid Substances 0.000 claims description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 2
- 238000003825 pressing Methods 0.000 claims description 2
- 239000004208 shellac Substances 0.000 claims description 2
- 229940113147 shellac Drugs 0.000 claims description 2
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 claims description 2
- 235000013874 shellac Nutrition 0.000 claims description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims description 2
- 239000008107 starch Substances 0.000 claims description 2
- 125000005591 trimellitate group Chemical group 0.000 claims description 2
- 229920001285 xanthan gum Polymers 0.000 claims description 2
- 238000009492 tablet coating Methods 0.000 claims 6
- 239000002700 tablet coating Substances 0.000 claims 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims 1
- YBCVMFKXIKNREZ-UHFFFAOYSA-N acoh acetic acid Chemical compound CC(O)=O.CC(O)=O YBCVMFKXIKNREZ-UHFFFAOYSA-N 0.000 claims 1
- 239000000654 additive Substances 0.000 claims 1
- 230000000996 additive effect Effects 0.000 claims 1
- 239000002518 antifoaming agent Substances 0.000 claims 1
- 239000003086 colorant Substances 0.000 claims 1
- 125000005397 methacrylic acid ester group Chemical group 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 5
- 150000003839 salts Chemical class 0.000 abstract description 4
- 239000000825 pharmaceutical preparation Substances 0.000 abstract description 2
- 229940126601 medicinal product Drugs 0.000 abstract 2
- 206010030216 Oesophagitis Diseases 0.000 abstract 1
- 208000006881 esophagitis Diseases 0.000 abstract 1
- 239000002775 capsule Substances 0.000 description 10
- 210000002784 stomach Anatomy 0.000 description 9
- 239000010410 layer Substances 0.000 description 7
- 230000007794 irritation Effects 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 239000002552 dosage form Substances 0.000 description 4
- 238000005538 encapsulation Methods 0.000 description 4
- 210000003238 esophagus Anatomy 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 239000002253 acid Substances 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 238000007906 compression Methods 0.000 description 3
- 230000006835 compression Effects 0.000 description 3
- 239000006185 dispersion Substances 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 238000004091 panning Methods 0.000 description 3
- OGSPWJRAVKPPFI-UHFFFAOYSA-N Alendronic Acid Chemical compound NCCCC(O)(P(O)(O)=O)P(O)(O)=O OGSPWJRAVKPPFI-UHFFFAOYSA-N 0.000 description 2
- 208000020084 Bone disease Diseases 0.000 description 2
- 239000001828 Gelatine Substances 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- IIDJRNMFWXDHID-UHFFFAOYSA-N Risedronic acid Chemical compound OP(=O)(O)C(P(O)(O)=O)(O)CC1=CC=CN=C1 IIDJRNMFWXDHID-UHFFFAOYSA-N 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 229940062527 alendronate Drugs 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 230000001079 digestive effect Effects 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 239000006186 oral dosage form Substances 0.000 description 2
- WRUUGTRCQOWXEG-UHFFFAOYSA-N pamidronate Chemical compound NCCC(O)(P(O)(O)=O)P(O)(O)=O WRUUGTRCQOWXEG-UHFFFAOYSA-N 0.000 description 2
- 229940046231 pamidronate Drugs 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229940089617 risedronate Drugs 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 230000009747 swallowing Effects 0.000 description 2
- 230000020192 tolerance induction in gut-associated lymphoid tissue Effects 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 229940122361 Bisphosphonate Drugs 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- ISZIECUHZQGAPV-UHFFFAOYSA-N NP(O)(=O)OP(O)=O Chemical class NP(O)(=O)OP(O)=O ISZIECUHZQGAPV-UHFFFAOYSA-N 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- ALZBUNKFMZIVDG-UHFFFAOYSA-N OC(CC1=CC=CN=C1)(OP(O)=O)OP(O)=O Chemical compound OC(CC1=CC=CN=C1)(OP(O)=O)OP(O)=O ALZBUNKFMZIVDG-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 208000027067 Paget disease of bone Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- DKJJVAGXPKPDRL-UHFFFAOYSA-N Tiludronic acid Chemical compound OP(O)(=O)C(P(O)(O)=O)SC1=CC=C(Cl)C=C1 DKJJVAGXPKPDRL-UHFFFAOYSA-N 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 229920013820 alkyl cellulose Polymers 0.000 description 1
- 125000000217 alkyl group Chemical class 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 150000004663 bisphosphonates Chemical class 0.000 description 1
- 208000016738 bone Paget disease Diseases 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 239000011247 coating layer Substances 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 239000002274 desiccant Substances 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- XQRLCLUYWUNEEH-UHFFFAOYSA-N diphosphonic acid Chemical compound OP(=O)OP(O)=O XQRLCLUYWUNEEH-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 239000002360 explosive Substances 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 210000001156 gastric mucosa Anatomy 0.000 description 1
- 201000005917 gastric ulcer Diseases 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 231100001261 hazardous Toxicity 0.000 description 1
- 229920013821 hydroxy alkyl cellulose Chemical class 0.000 description 1
- 229960005236 ibandronic acid Drugs 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 239000011256 inorganic filler Substances 0.000 description 1
- 229910003475 inorganic filler Inorganic materials 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000008297 liquid dosage form Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 229940117841 methacrylic acid copolymer Drugs 0.000 description 1
- 125000005395 methacrylic acid group Chemical group 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 235000012771 pancakes Nutrition 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 229940100467 polyvinyl acetate phthalate Drugs 0.000 description 1
- 125000001453 quaternary ammonium group Chemical group 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 239000008299 semisolid dosage form Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229940019375 tiludronate Drugs 0.000 description 1
- 230000036269 ulceration Effects 0.000 description 1
- 210000002438 upper gastrointestinal tract Anatomy 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 239000011023 white opal Substances 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
- A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physical Education & Sports Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Oncology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Cosmetics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19615812A DE19615812A1 (de) | 1996-04-20 | 1996-04-20 | Pharmazeutische Zubereitung enthaltend Diphosphonsäuren zur oralen Applikation |
| DE19615812.5 | 1996-04-20 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU98120909A RU98120909A (ru) | 2000-09-10 |
| RU2193881C2 true RU2193881C2 (ru) | 2002-12-10 |
Family
ID=7791961
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU98120909/14A RU2193881C2 (ru) | 1996-04-20 | 1997-04-21 | Фармацевтический препарат для орального применения, содержащий ибандронат |
Country Status (26)
| Country | Link |
|---|---|
| US (2) | US6143326A (enExample) |
| EP (2) | EP0936913B2 (enExample) |
| JP (2) | JP5037746B2 (enExample) |
| CN (1) | CN101152160A (enExample) |
| AR (2) | AR006652A1 (enExample) |
| AT (1) | ATE404207T1 (enExample) |
| AU (1) | AU722516B2 (enExample) |
| BR (1) | BR9708785A (enExample) |
| CA (1) | CA2251886C (enExample) |
| CO (1) | CO4820394A1 (enExample) |
| CZ (1) | CZ297341B6 (enExample) |
| DE (2) | DE19615812A1 (enExample) |
| DK (1) | DK0936913T4 (enExample) |
| ES (1) | ES2313735T5 (enExample) |
| HU (1) | HU228389B1 (enExample) |
| IL (2) | IL126655A (enExample) |
| NO (1) | NO319162B1 (enExample) |
| NZ (1) | NZ332314A (enExample) |
| PA (1) | PA8427301A1 (enExample) |
| PL (2) | PL191910B1 (enExample) |
| PT (1) | PT936913E (enExample) |
| RU (1) | RU2193881C2 (enExample) |
| SI (1) | SI0936913T2 (enExample) |
| TR (1) | TR199802108T2 (enExample) |
| WO (1) | WO1997039755A1 (enExample) |
| ZA (1) | ZA973331B (enExample) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2262923C2 (ru) * | 2003-12-25 | 2005-10-27 | Государственное образовательное учреждение высшего профессионального образования Курский государственный медицинский университет Министерства здравоохранения Российской Федерации | Иммобилизованная форма доксорубицина |
| WO2009075601A1 (fr) * | 2007-12-12 | 2009-06-18 | Alexander Valerievich Melnik | Moyen d'indication d'une éventuelle prédisposition de chats à une maladie (variantes) et procédé de détermination de troubles de la santé chez les chats |
| RU2381791C2 (ru) * | 2005-04-15 | 2010-02-20 | Дзе Проктер Энд Гэмбл Компани | Лекарственные формы ризедроната |
| RU2485957C1 (ru) * | 2012-03-16 | 2013-06-27 | Государственное бюджетное образовательное учреждение дополнительного профессионального образования "Российская медицинская академия последипломного образования" Министерства здравоохранения Российской Федерации (ГБОУ ДПО РМАПО Минздрава России) | Средство для лечения низкообменного варианта заболевания скелета у больных с хронической почечной недостаточностью |
| RU2599023C2 (ru) * | 2011-06-17 | 2016-10-10 | Эвоник Рем ГмбХ | Покрывающая композиция, подходящая для фармацевтических или нутрицевтических лекарственных форм |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19615812A1 (de) | 1996-04-20 | 1997-10-23 | Boehringer Mannheim Gmbh | Pharmazeutische Zubereitung enthaltend Diphosphonsäuren zur oralen Applikation |
| PL337813A1 (en) * | 1997-06-11 | 2000-09-11 | Procter & Gamble | Coated tablet with a coating ensuring safe administration for upper portion of the gastrointestinal tract |
| EP0998932A1 (de) | 1998-10-09 | 2000-05-10 | Boehringer Mannheim Gmbh | Feste pharmazeutische Darreichungsform enthaltend Diphosphonsäure oder deren Salze und Verfahren zu ihrer Herstellung |
| AR024462A1 (es) | 1999-07-01 | 2002-10-02 | Merck & Co Inc | Tabletas farmaceuticas |
| US6476006B2 (en) | 2000-06-23 | 2002-11-05 | Teva Pharmaceutical Industries, Ltd. | Composition and dosage form for delayed gastric release of alendronate and/or other bis-phosphonates |
| US6881420B2 (en) | 2000-06-23 | 2005-04-19 | Teva Pharmaceutical Industries Ltd. | Compositions and dosage forms for gastric delivery of irinotecan and methods of treatment that use it to inhibit cancer cell proliferation |
| US7674480B2 (en) * | 2000-06-23 | 2010-03-09 | Teva Pharmaceutical Industries Ltd. | Rapidly expanding composition for gastric retention and controlled release of therapeutic agents, and dosage forms including the composition |
| KR100863146B1 (ko) * | 2000-07-17 | 2008-10-14 | 아스텔라스세이야쿠 가부시키가이샤 | 경구 흡수 개선 의약 조성물 |
| AR034199A1 (es) * | 2001-02-01 | 2004-02-04 | Riderway Corp | Composicion farmacologica liquida para el tratamiento de enfermedades oseas y procedimientos para su elaboracion |
| JP2002332235A (ja) * | 2001-02-01 | 2002-11-22 | Riderway Corp | 骨疾患治療用液体医薬組成物 |
| BR0209360A (pt) * | 2001-05-02 | 2004-06-08 | Novartis Ag | Método de administração de bisfosfonatos por inalação no tratamento ou prevenção de reabsorção óssea e osteoporose |
| DK1355633T3 (da) * | 2001-12-19 | 2005-04-04 | Astrazeneca Ab | Ny filmcoating, der indeholder en ethylacrylat/methylmethacrylat-copolymer og polyvinylacetat |
| HUP0402267A3 (en) * | 2001-12-21 | 2007-05-29 | Procter & Gamble | Method for treatment of bone disorders |
| AU2003211146B2 (en) | 2002-02-21 | 2007-07-19 | Valeant International (Barbados) Srl | Controlled release dosage forms |
| BR0308901A (pt) * | 2002-05-10 | 2005-01-04 | Hoffmann La Roche | ácidos bisfosfÈnicos para tratamento e prevenção de osteoporose |
| GB0229258D0 (en) * | 2002-12-16 | 2003-01-22 | Boots Healthcare Int Ltd | Medicinal compositions |
| ES2530791T3 (es) * | 2002-12-20 | 2015-03-05 | Hoffmann La Roche | Formulación de ibandronato de altas dosis |
| TR200300510A2 (tr) * | 2003-04-18 | 2004-11-22 | Sanovel �La� Sanay� Ve T�Caret A.�. | Dağılan alendronat mikropartikül formülasyonu |
| GB0403628D0 (en) * | 2004-02-18 | 2004-03-24 | Arrow Group Ltd | Compression-coated tablets and the manufacture thereof |
| US20080286359A1 (en) * | 2004-05-24 | 2008-11-20 | Richard John Dansereau | Low Dosage Forms Of Risedronate Or Its Salts |
| US20080287400A1 (en) * | 2004-05-24 | 2008-11-20 | Richard John Dansereau | Low Dosage Forms Of Risedronate Or Its Salts |
| US7645460B2 (en) * | 2004-05-24 | 2010-01-12 | The Procter & Gamble Company | Dosage forms of risedronate |
| WO2008128056A1 (en) * | 2004-10-08 | 2008-10-23 | The Board Of Trustees Of The University Of Illinois | Bisphosphonate compounds and methods with enhanced potency for multiple targets including fpps, ggpps, and dpps |
| WO2006039721A2 (en) * | 2004-10-08 | 2006-04-13 | The Board Of Trustees Of The University Of Illinois | Bisphosphonate compounds and methods for bone resorption diseases, cancer, bone pain, immune disorders, and infectious diseases |
| US20070191315A1 (en) * | 2006-02-16 | 2007-08-16 | Bengt Bergstrom | Method for administering ibandronate |
| EP2001486A4 (en) * | 2006-03-17 | 2010-12-29 | Univ Illinois | BIPHOSPHONATE COMPOUNDS AND CORRESPONDING METHODS |
| CN101495101B (zh) * | 2006-07-25 | 2012-02-29 | 兴和株式会社 | 糖衣制剂及其制造方法 |
| GB0616794D0 (en) * | 2006-08-24 | 2006-10-04 | Arrow Int Ltd | Solid dosage form |
| US20080139514A1 (en) * | 2006-11-29 | 2008-06-12 | Subhash Pandurang Gore | Diphosphonic acid pharmaceutical compositions |
| CA2570949A1 (en) * | 2006-12-12 | 2008-06-12 | Apotex Pharmachem Inc. | Ibandronate sodium propylene glycol solvate and processes for the preparation thereof |
| EP2210596A1 (en) * | 2009-01-22 | 2010-07-28 | Laboratorios Liconsa, S.A. | Pharmaceutical composition of ibandronate sodium salt or a hydrate thereof |
| CN103079596B (zh) | 2010-08-31 | 2015-08-19 | 东丽株式会社 | 药物固体制剂用的包衣剂、药物用膜制剂以及包覆药物固体制剂 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0421921B1 (de) * | 1989-09-07 | 1994-04-27 | Ciba-Geigy Ag | Doppelt beschichtete Granulate |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE965825C (de) | 1949-10-30 | 1957-06-19 | Walter Kloepfer Dipl Ing Dr In | Zur Antennenebene senkrecht polarisierter Strahler |
| US4820698A (en) * | 1985-11-04 | 1989-04-11 | The Procter & Gamble Company | Antimicrobial agents and process for their manufacture |
| DE3623397A1 (de) * | 1986-07-11 | 1988-01-14 | Boehringer Mannheim Gmbh | Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel |
| US5098717A (en) * | 1987-12-09 | 1992-03-24 | Thames Pharmacal Co., Inc. | Method of treatment for pruritus |
| EP0550385A1 (de) * | 1991-12-19 | 1993-07-07 | Ciba-Geigy Ag | Peroral zu verabreichende pharmazeutische Zusammensetzungen, die Methandiphosphonsäure-Derivate und 18-Krone-6 Ether enthalten |
| TW237386B (enExample) * | 1992-04-15 | 1995-01-01 | Ciba Geigy | |
| US5358941A (en) * | 1992-12-02 | 1994-10-25 | Merck & Co., Inc. | Dry mix formulation for bisphosphonic acids with lactose |
| CZ287984B6 (cs) * | 1993-05-15 | 2001-03-14 | Roche Diagnostics Gmbh | Tableta se zlepšenou biodostupností účinné látky, kyseliny klodronové, a způsob její výroby |
| US5431920A (en) * | 1993-09-21 | 1995-07-11 | Merck Frosst, Canada, Inc. | Enteric coated oral compositions containing bisphosphonic acid antihypercalcemic agents |
| TW390813B (en) * | 1994-04-29 | 2000-05-21 | Merck & Co Inc | Wet granulation formulation for bisphosphonic acids |
| DE19615812A1 (de) | 1996-04-20 | 1997-10-23 | Boehringer Mannheim Gmbh | Pharmazeutische Zubereitung enthaltend Diphosphonsäuren zur oralen Applikation |
| US5803321A (en) * | 1996-11-12 | 1998-09-08 | Randy Hangers, Lll | Hanger with ganging element |
| US20060045865A1 (en) * | 2004-08-27 | 2006-03-02 | Spherics, Inc. | Controlled regional oral delivery |
-
1996
- 1996-04-20 DE DE19615812A patent/DE19615812A1/de not_active Withdrawn
-
1997
- 1997-04-08 CO CO97017783A patent/CO4820394A1/es unknown
- 1997-04-15 AR ARP970101504A patent/AR006652A1/es active IP Right Grant
- 1997-04-17 PA PA19978427301A patent/PA8427301A1/es unknown
- 1997-04-18 ZA ZA973331A patent/ZA973331B/xx unknown
- 1997-04-21 NZ NZ332314A patent/NZ332314A/xx not_active IP Right Cessation
- 1997-04-21 RU RU98120909/14A patent/RU2193881C2/ru active
- 1997-04-21 PL PL369034A patent/PL191910B1/pl unknown
- 1997-04-21 ES ES97918146T patent/ES2313735T5/es not_active Expired - Lifetime
- 1997-04-21 WO PCT/EP1997/001940 patent/WO1997039755A1/de not_active Ceased
- 1997-04-21 DE DE59712959T patent/DE59712959D1/de not_active Expired - Lifetime
- 1997-04-21 DK DK97918146.8T patent/DK0936913T4/da active
- 1997-04-21 AU AU26382/97A patent/AU722516B2/en not_active Expired
- 1997-04-21 TR TR1998/02108T patent/TR199802108T2/xx unknown
- 1997-04-21 PL PL329347A patent/PL191363B1/pl unknown
- 1997-04-21 CN CNA2007101536726A patent/CN101152160A/zh active Pending
- 1997-04-21 AT AT97918146T patent/ATE404207T1/de active
- 1997-04-21 IL IL12665597A patent/IL126655A/en not_active IP Right Cessation
- 1997-04-21 CZ CZ0336498A patent/CZ297341B6/cs not_active IP Right Cessation
- 1997-04-21 HU HU9903407A patent/HU228389B1/hu unknown
- 1997-04-21 EP EP97918146A patent/EP0936913B2/de not_active Expired - Lifetime
- 1997-04-21 EP EP06001911.4A patent/EP1658852B1/de not_active Revoked
- 1997-04-21 BR BR9708785A patent/BR9708785A/pt not_active Application Discontinuation
- 1997-04-21 IL IL16393097A patent/IL163930A0/xx unknown
- 1997-04-21 JP JP53771197A patent/JP5037746B2/ja not_active Expired - Lifetime
- 1997-04-21 PT PT97918146T patent/PT936913E/pt unknown
- 1997-04-21 CA CA002251886A patent/CA2251886C/en not_active Expired - Lifetime
- 1997-04-21 SI SI9730781T patent/SI0936913T2/sl unknown
- 1997-04-21 US US09/147,149 patent/US6143326A/en not_active Expired - Lifetime
-
1998
- 1998-10-19 NO NO19984881A patent/NO319162B1/no not_active IP Right Cessation
-
2003
- 2003-09-12 US US10/660,785 patent/US20050089573A1/en not_active Abandoned
-
2006
- 2006-04-24 AR ARP060101621A patent/AR054350A2/es unknown
-
2008
- 2008-07-08 JP JP2008178294A patent/JP5557989B2/ja not_active Expired - Lifetime
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0421921B1 (de) * | 1989-09-07 | 1994-04-27 | Ciba-Geigy Ag | Doppelt beschichtete Granulate |
Non-Patent Citations (1)
| Title |
|---|
| МАШКОВСКИЙ М.Д. Лекарственные средства. - М.: Медицина, 1993, т.1, с.395-397. * |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2262923C2 (ru) * | 2003-12-25 | 2005-10-27 | Государственное образовательное учреждение высшего профессионального образования Курский государственный медицинский университет Министерства здравоохранения Российской Федерации | Иммобилизованная форма доксорубицина |
| RU2381791C2 (ru) * | 2005-04-15 | 2010-02-20 | Дзе Проктер Энд Гэмбл Компани | Лекарственные формы ризедроната |
| WO2009075601A1 (fr) * | 2007-12-12 | 2009-06-18 | Alexander Valerievich Melnik | Moyen d'indication d'une éventuelle prédisposition de chats à une maladie (variantes) et procédé de détermination de troubles de la santé chez les chats |
| RU2599023C2 (ru) * | 2011-06-17 | 2016-10-10 | Эвоник Рем ГмбХ | Покрывающая композиция, подходящая для фармацевтических или нутрицевтических лекарственных форм |
| US9668977B2 (en) | 2011-06-17 | 2017-06-06 | Evonik Röhm Gmbh | Coating composition suitable for pharmaceutical or nutraceutical dosage forms |
| RU2485957C1 (ru) * | 2012-03-16 | 2013-06-27 | Государственное бюджетное образовательное учреждение дополнительного профессионального образования "Российская медицинская академия последипломного образования" Министерства здравоохранения Российской Федерации (ГБОУ ДПО РМАПО Минздрава России) | Средство для лечения низкообменного варианта заболевания скелета у больных с хронической почечной недостаточностью |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6143326A (en) | Oral pharmaceutical preparation containing ibandronat | |
| RU2359678C2 (ru) | Лекарственные формы на основе бисфосфонатов | |
| RU2381791C2 (ru) | Лекарственные формы ризедроната | |
| RU2120798C1 (ru) | Твердая фармацевтическая композиция для перорального введения | |
| KR100496086B1 (ko) | 비스포스포네이트를 포함하는 경구 투여용 약학 조성물의 제조 방법 | |
| CA2661547A1 (en) | Solid dosage form | |
| KR100482931B1 (ko) | 이반드로네이트를함유하는경구용약제학적제제 | |
| HK1118714A (en) | Oral pharmaceutical preparation containing ibandronat |